Part One: The Question of MRD in CLL Therapy
The HemOnc Pulse
Optimizing Treatment Strategies for Young CLL Patients
This chapter examines the decision-making process for referring a younger CLL patient to cell therapy after failing a BTK inhibitor and showing chemo sensitivity, focusing on CAR-T therapy and MRD monitoring. The discussion evaluates different clinical trials, emphasizing the impact of hazard ratios on treatment decisions and addressing challenges unique to CLL, such as Richter's transformation and immune reconstitution.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
